A New Hope for Cancer Therapy with Liquid Knife & Immuno Therapy: UMIPIC

Abstract

This work is licensed under Creative Commons Attribution 4.0 License CTCMS.MS.ID.000524. Short CommunicationRecent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy always produce the side effect like loss hair, vomit and neutropenia. Because of the extremely toxic side effects, many cancer patients cannot successfully complete a complete course of chemotherapy, and some even die from the side effects of chemotherapy due to a patient's poor tolerance. The extreme side effects of anti-cancer drugs are often caused by the poor target specificity of such drugs regarding the tumor in the patient's body.

Immunity Reaction by Chemotherapy Drug With DNP or penicillin Intratumoral Injection in Mice Bearing Tumor

“…Therapies of increased complexity were inspired by the study of a local anticancer drug delivery, with reactive oxygen species (ROS), drugs in an H 2 O 2 solution for easier injection and even distribution within tumor for a prolonged release 3 . When the anticancer drug is injected intratumorally, this immunological therapy battles induced immunological reactions [4][5][6][7][8][9] . Intratumoral injections with a single drug or combination of drugs with hapten is extensively researched [4][5][6][7][8][9] .…”

“…Limited research exists regarding how hapten enhances survival time when injected intratumorally with anticancer drugs. The ndings of this research indicate that acute in ammation increases in tumors due to CD4 and CD8 increasing [6][7][8][9] . No reports explain the relationship between tumors' in ammation, induced by intratumoral injection of dug and hapten, and induced acute in ammation.…”

“…When the anticancer drug is injected intratumorally, this immunological therapy battles induced immunological reactions [4][5][6][7][8][9] . Intratumoral injections with a single drug or combination of drugs with hapten is extensively researched [4][5][6][7][8][9] . Limited research exists regarding how hapten enhances survival time when injected intratumorally with anticancer drugs.…”